Y-Mabs Therapeutics (YMAB) Stock Forecast & Price Target

Compare

516 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

YMAB Analyst Ratings

Moderate Buy

6 Buy

0 Hold

2 Sell

Based on 8 analysts giving stock ratings to

Y-Mabs

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

YMAB Stock 12 Month Forecast

Average Price Target

$13.86

▲(163.00%Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Y-Mabs Therapeutics in the last 3 months. The average price target is $13.86 with a high forecast of $26.00 and a low forecast of $3.00. The average price target represents a 163.00% change from the last price of $5.27.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","27":"$27","8.25":"$8.25","14.5":"$14.5","20.75":"$20.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.25,14.5,20.75,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.74,6.375384615384616,8.010769230769231,9.646153846153846,11.28153846153846,12.916923076923077,14.552307692307691,16.18769230769231,17.823076923076922,19.458461538461535,21.09384615384615,22.729230769230767,24.364615384615384,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.74,5.441538461538462,6.143076923076923,6.844615384615384,7.546153846153846,8.247692307692308,8.94923076923077,9.65076923076923,10.352307692307692,11.053846153846154,11.755384615384614,12.456923076923076,13.158461538461538,{"y":13.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.74,4.6061538461538465,4.472307692307693,4.338461538461539,4.204615384615384,4.070769230769231,3.936923076923077,3.8030769230769232,3.6692307692307695,3.5353846153846153,3.4015384615384616,3.2676923076923075,3.1338461538461537,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.1,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.83,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.64,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.31,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.21,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.74,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.56,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.11,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$26.00

Average Price Target$13.86

Lowest Price Target$3.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robert BurnsH.C. Wainwright

H.C. Wainwright

$11

Buy

108.73%

Upside

Reiterated

06/03/25

Promising R&D Developments and New Radiohapten Propel Y-Mabs Therapeutics to a Buy Rating

Nicole GerminoTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/29/25

Truist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)

Justin WalshJonesTrading

JonesTrading

$18

Buy

241.56%

Upside

Reiterated

05/29/25

Optimistic Outlook on Y-mAbs Therapeutics' GD2-SADA Platform Despite Developmental Delays

Jeff JonesOppenheimer

Oppenheimer

$20→$15

Buy

184.63%

Upside

Reiterated

05/29/25

Oppenheimer Remains a Buy on Y-Mabs Therapeutics (YMAB)

William MaughanClear Street

Clear Street

$17

Buy

222.58%

Upside

Reiterated

05/28/25

Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB)

Michael UlzMorgan Stanley

Morgan Stanley

Sell

32.83%

Upside

Reiterated

05/28/25

Prolonged Development Timelines and Limited Near-Term Catalysts Lead to Sell Rating for Y-Mabs Therapeutics

John NewmanCanaccord Genuity

Canaccord Genuity

$26

Buy

393.36%

Upside

Reiterated

05/28/25

Y-Mabs Therapeutics: Buy Rating Affirmed on Promising SADA Program Advancements and Market Expansion Potential

Alec StranahanBank of America Securities

Bank of America Securities

Sell

-43.07%

Downside

Reiterated

05/28/25

Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline

Kemp DolliverBrookline Capital Markets

Brookline Capital Markets

$17→$16

Buy

203.61%

Upside

Reiterated

03/04/25

Y-mAbs Therapeutics (YMAB) PT Lowered to $16 at Brookline Capital MarketsBrookline Capital Markets analyst Kemp Dolliver lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $16.00 (from $17.00) while maintaining a Buy rating.

Li WatsekCantor Fitzgerald

Cantor Fitzgerald

$20→$19

Buy

260.53%

Upside

Reiterated

03/04/25

Y-mAbs Therapeutics (YMAB) PT Lowered to $19 at Cantor FitzgeraldCantor Fitzgerald analyst Li Warsek lowered the price target on Y-mAbs Therapeutics (NASDAQ: YMAB) to $19.00 (from $20.00) while maintaining a Overweight rating.

David NierengartenWedbush

Wedbush

$23

Buy

336.43%

Upside

Reiterated

03/03/25

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robert BurnsH.C. Wainwright

H.C. Wainwright

$11

Buy

108.73%

Upside

Reiterated

06/03/25

Promising R&D Developments and New Radiohapten Propel Y-Mabs Therapeutics to a Buy Rating

Nicole GerminoTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/29/25

Truist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)

Justin WalshJonesTrading

JonesTrading

$18

Buy

241.56%

Upside

Reiterated

05/29/25

Optimistic Outlook on Y-mAbs Therapeutics' GD2-SADA Platform Despite Developmental Delays

Jeff JonesOppenheimer

Oppenheimer

$20→$15

Buy

184.63%

Upside

Reiterated

05/29/25

Oppenheimer Remains a Buy on Y-Mabs Therapeutics (YMAB)

William MaughanClear Street

Clear Street

$17

Buy

222.58%

Upside

Reiterated

05/28/25

Clear Street Reaffirms Their Buy Rating on Y-Mabs Therapeutics (YMAB)

Michael UlzMorgan Stanley

Morgan Stanley

Sell

32.83%

Upside

Reiterated

05/28/25

Prolonged Development Timelines and Limited Near-Term Catalysts Lead to Sell Rating for Y-Mabs Therapeutics

John NewmanCanaccord Genuity

Canaccord Genuity

$26

Buy

393.36%

Upside

Reiterated

05/28/25

Y-Mabs Therapeutics: Buy Rating Affirmed on Promising SADA Program Advancements and Market Expansion Potential

Alec StranahanBank of America Securities

Bank of America Securities

Sell

-43.07%

Downside

Reiterated

05/28/25

Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline

Kemp DolliverBrookline Capital Markets

Brookline Capital Markets

$17→$16

Buy

203.61%

Upside

Reiterated

03/04/25

Li WatsekCantor Fitzgerald

Cantor Fitzgerald

$20→$19

Buy

260.53%

Upside

Reiterated

03/04/25

David NierengartenWedbush

Wedbush

$23

Buy

336.43%

Upside

Reiterated

03/03/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Y-Mabs Therapeutics

1 Month

xxx

Success Rate

6/9 ratings generated profit

Average Return

+3.77%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +3.77% per trade.

3 Months

xxx

Success Rate

5/9 ratings generated profit

Average Return

+11.74%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +11.74% per trade.

1 Year

William MaughanClear Street

Success Rate

10/14 ratings generated profit

Average Return

+51.09%

reiterated a buy rating 12 days ago

Copying William Maughan's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +51.09% per trade.

2 Years

xxx

Success Rate

6/9 ratings generated profit

Average Return

+21.58%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +21.58% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

YMAB Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, YMAB has received 13 Buy Ratings, 0 Hold Ratings, and 6 Sell Ratings. YMAB average Analyst price target in the past 3 months is 13.86.

Each month's total comprises the sum of three months' worth of ratings.

YMAB Financial Forecast

YMAB Earnings Forecast

Next quarter’s earnings estimate for YMAB is -$0.26 with a range of -$0.31 to -$0.19. The previous quarter’s EPS was -$0.12. YMAB beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year YMAB has Outperformed its overall industry.

YMAB Sales Forecast

Next quarter’s sales forecast for YMAB is $18.37M with a range of $18.00M to $19.30M. The previous quarter’s sales results were $20.90M. YMAB beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year YMAB has Outperformed its overall industry.

YMAB Stock Forecast FAQ

What is YMAB’s average 12-month price target, according to analysts?

Based on analyst ratings, Y-Mabs Therapeutics’s 12-month average price target is 13.86.

What is YMAB’s upside potential, based on the analysts’ average price target?

Y-Mabs Therapeutics has 163.00% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is YMAB a Buy, Sell or Hold?

Y-Mabs Therapeutics has a consensus rating of Moderate Buy which is based on 6 buy ratings, 0 hold ratings and 2 sell ratings.

What is Y-Mabs Therapeutics’s price target?

The average price target for Y-Mabs Therapeutics is 13.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $26.00 ,the lowest forecast is $3.00. The average price target represents 163.00% Increase from the current price of $5.27.

What do analysts say about Y-Mabs Therapeutics?

Y-Mabs Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of YMAB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Y-Mabs Therapeutics (YMAB) Stock Forecast & Price Target

YMAB Analyst Ratings

YMAB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Y-Mabs Therapeutics

YMAB Analyst Recommendation Trends

YMAB Financial Forecast

YMAB Earnings Forecast

YMAB Sales Forecast

YMAB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts